NEJM: Pfizer COVID-19 drug Paxlovid is ineffective in young people
- Why Botulinum Toxin Reigns as One of the Deadliest Poisons?
- FDA Approves Pfizer’s One-Time Gene Therapy for Hemophilia B: $3.5 Million per Dose
- Aspirin: Study Finds Greater Benefits for These Colorectal Cancer Patients
- Cancer Can Occur Without Genetic Mutations?
- Statins Lower Blood Lipids: How Long is a Course?
- Warning: Smartwatch Blood Sugar Measurement Deemed Dangerous
NEJM: Pfizer COVID-19 drug Paxlovid is ineffective in young people
- Red Yeast Rice Scare Grips Japan: Over 114 Hospitalized and 5 Deaths
- Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
NEJM: Pfizer COVID-19 drug Paxlovid is ineffective in young people
According to the Associated Press on August 24, according to an observational study published in the “New England Journal of Medicine”, a study conducted in Israel showed that Pfizer’s COVID-19 oral drug Paxlovid has little effect on young adults. The effect was significant only in high-risk patients 65 years of age or older.
“New England Journal of Medicine” paper “Nirmatrelvir use and COVID-19 severe consequences during the surge of Omicron” ( Nirmatrelvir is Pfizer’s COVID-19 oral drug Paxlovid )
The paper concludes that there is no evidence that Paxlovid is effective in young people
However, the report also pointed out that the observational study has limitations. Instead of enrolling patients in a randomized study with a control group, it compiled data from a large Israeli health system.
“Paxlovid remains important for high-risk groups, such as the elderly and those with compromised immune systems,” said a University of Minnesota researcher and physician who was not involved in the study. “But for the vast majority of Americans right now, it’s really not useful.”
A Pfizer spokesman declined to comment on the reported findings, published in the New England Journal of Medicine.
It’s worth noting, however, that Pfizer reported earlier this summer that a separate study of Paxlovid in healthy adults, vaccinated or unvaccinated, showed the drug showed no apparent benefit, although the findings also Not published in a medical journal.
Pfizer’s Paxlovid is currently the treatment of choice for the coronavirus in the United States. The Biden administration has spent more than $10 billion buying the drug and selling it in thousands of pharmacies.
According to U.S. federal records, more than 3.9 million prescriptions have been filled since Paxlovid was authorized for use. A course of treatment is three tablets twice a day for five days.
U.S. government officials have been working to increase the use of Paxlovid for months, opening thousands of sites where patients who test positive can fill out prescriptions. Last month, U.S. officials further expanded access to allow pharmacists to prescribe the drug.
Yet a Biden administration will soon stop paying for it all.
According to earlier reports by US media, White House COVID-19 epidemic response coordinator Ashish Jha said at an event hosted by the American Chamber of Commerce Foundation on the 16th that the Biden administration will stop purchasing COVID-19 vaccines, drugs and tests as early as this fall.
The corresponding products and services will be commercialized, and this part of the responsibility will be transferred to the private insurance market, it said. Insurers will then be able to set new criteria for when to pay patients for Paxlovid.
NEJM: Pfizer COVID-19 drug Paxlovid is ineffective in young people
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
